Compare Acadia Healthcare Company Inc (ACHC) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Acadia Healthcare Company Inc vs Biogen Inc — how do they compare? Acadia Healthcare Company Inc trades at $31.4 (market cap $2.90B), while Biogen Inc trades at $205.08 (market cap $30.13B). The key difference: Biogen Inc is far larger — about 10.4× Acadia Healthcare Company Inc's market cap. Which is the better fit depends on your goals.
| ACHC | BIIB | |
|---|---|---|
Market Cap | $2.90B | $30.13B |
Sector | Health | Health |
52-Week High | $35.61 | $216.63 |
52-Week Low | $11.68 | $128.93 |
Enterprise Value | $5.29B | $37.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.14, down 2.01% today, with a neutral technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $0.38, beating estimates, but maintains a net loss of -$1.10B for 2025. Analyst consensus is bullish with a $36.00 price target, though ongoing legal investigations and negative profit margins present headwinds. Cash flow from operations improved to $211M in 2026, supporting operational stability amid challenges.
The outlook for ACHC hinges on execution of its turnaround strategy and resolution of legal issues. Upside potential exists if EBITDA guidance improvements and admissions growth persist, but risks from litigation and sustained losses warrant caution. The stock's current valuation at a P/E of 19.82 and P/S of 0.84 may attract value investors if profitability recovers.
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
